Patent application number | Description | Published |
20120121667 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 05-17-2012 |
20120189705 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are . also provided. | 07-26-2012 |
20130122065 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 05-16-2013 |
20140037721 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 02-06-2014 |
20140056975 | Pharmaceutical Composition - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 02-27-2014 |
Patent application number | Description | Published |
20110311491 | TREATMENT OF SARCOIDOSIS USING PLACENTAL STEM CELLS - Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof. | 12-22-2011 |
20120156230 | TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an injury to the central nervous system, such as a spinal cord injury or a traumatic brain injury, using placental stem cells and placental multipotent stem cells described herein, and populations of such placental cells. | 06-21-2012 |
20120164114 | TREATMENT OF IMMUNE-RELATED DISEASES AND DISORDERS USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease. | 06-28-2012 |
20120201787 | TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating spinal cord and traumatic brain injuries using cells from amnion, and populations of such cells, referred to herein as “amnion derived adherent cells” (“AMDACs”). | 08-09-2012 |
20140219970 | TREATMENT OF SARCOIDOSIS USING PLACENTAL STEM CELLS - Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof. | 08-07-2014 |
Patent application number | Description | Published |
20090263345 | Otic compositions for the treatment of infections of the internal and external ear in mammals - Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans. | 10-22-2009 |
20100197562 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention provides a novel class of biaryl compounds as inhibitors of ÿ2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the ÿ2C adrenergic receptors using such compounds or pharmaceutical compositions. | 08-05-2010 |
20100254934 | Ophthalmic Compositions Comprising Povidone-Iodine - A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. | 10-07-2010 |
20100291019 | Methods of Using Ophthalmic Compositions Comprising Povidone-Iodine - A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. | 11-18-2010 |
20120003174 | OTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS OF THE INTERNAL AND EXTERNAL EAR IN MAMMALS - Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans. | 01-05-2012 |
20120027716 | Povidone Iodine, A Novel Alternative Preservative For Ophthalmic Compositions - The invention includes a preserved ophthalmic preparation comprising povidone-iodine (PVP-I) at a concentration sufficient to preserve the ophthalmic preparation, and at least one member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial compound, an anti-allergy compound, and an anti-glaucoma compound. The invention also includes adding PVP-I to an ophthalmic composition in order to preserve the composition, wherein the PVP-I is added at a concentration sufficient to preserve the composition. | 02-02-2012 |
20130089510 | OTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS OF THE INTERNAL AND EXTERNAL EAR IN MAMMALS - Disclosed herein compositions including povidone-iodine (PVP-I) useful in the treatment of acute and chronic bacterial, viral and fungal infections of the internal, middle and external ear of mammals, including humans. | 04-11-2013 |
20130177522 | NON-IRRITATING OPTHALMIC POVIDONE-IODINE COMPOSITIONS - Disclosed are compositions and methods comprising povidone-iodine and a cooling-effective amount of a chemical agent. The compositions are useful to relieve mild ocular irritation, enhance ocular comfort, and to provide a refreshing effect and improved sensation, when the povidone-iodine solution is applied to the eye. | 07-11-2013 |
20130189217 | METHODS OF USING OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE - A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. | 07-25-2013 |
20130251666 | POVIDONE IODINE, A NOVEL ALTERNATIVE PRESERVATIVE FOR OPHTHALMIC COMPOSITIONS - The invention includes a preserved ophthalmic preparation comprising povidone-iodine (PVP-I) at a concentration sufficient to preserve the ophthalmic preparation, and at least one member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial compound, an anti-allergy compound, and an anti-glaucoma compound. The invention also includes adding PVP-I to an ophthalmic composition in order to preserve the composition, wherein the PVP-I is added at a concentration sufficient to preserve the composition. | 09-26-2013 |
20140369951 | OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE - A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. | 12-18-2014 |
20150038473 | STABLE POVIDONE-IODINE COMPOSITIONS WITH STEROIDS OR NON-STEROIDAL ANTI-INFLAMMATORIES - Disclosed are stable compositions comprising povidone-iodine and a steroid, and methods of making and using such compositions. Also disclosed herein are stable compositions comprising povidone-iodine and an NSAID, and methods of making and using such compositions. | 02-05-2015 |
Patent application number | Description | Published |
20130245204 | NOVEL AGENTS FOR REWORKABLE EPOXY RESINS - Compounds of formula I, uses as crosslinking agents or curing agents thereof, and resins obtained by using the compounds as crosslinking agents. | 09-19-2013 |
20140219949 | PHARMACEUTICAL COMPOSITIONS COMPRISING IODINE AND STEROID AND USES THEREOF FOR SINUS DISEASES - The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same. | 08-07-2014 |
20140221510 | REINFORCED COMPOSITE AND METHOD FOR RECYCLING THE SAME - The present invention relates to a reinforced composite and method for recycling the same. The reinforced composite comprises a reinforcement material in a cross-linked polymer matrix, wherein the cross-linked polymer comprises a cross-linking group derived from a curing agent represented by formula (I), Wherein R | 08-07-2014 |
20140322345 | NOVEL SLOW-RELEASING OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE IODINE - The present invention provides novel slow-releasing ophthalmic compositions containing Povidone Iodine (PVP-I) and uses thereof in the treatment of acute infections of at least one eye tissue from bacterial, mycobacterial, viral, fungal, or amoebic causes and for preventing such infections in appropriate clinical settings. Each of the ophthalmic compositions contains povidone iodine, osmotic pressure regulator, suspending agent and EDTA-Na, wherein povidone iodine exists as microsphere particles formed by PVP-I and sodium alginate. | 10-30-2014 |
Patent application number | Description | Published |
20100216694 | ANTIDIABETIC TRICYCLIC COMPOUNDS - Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 08-26-2010 |
20110207737 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES - Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety. | 08-25-2011 |
20120041012 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS - Substituted spirocyclic amines of structural formula I are selective antagonists of the somatostatin sub-type receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety. | 02-16-2012 |
Patent application number | Description | Published |
20080312306 | POLYMORPHS, SOLVATES, AND HYDRATE OF 5-(4'-FLUORO-2'-OXO-1',2'-DIHYDROSPIRO[CYCLOPROPANE-1,3'-INDOL]-5'-YL)-1-METHYL-1H-PYRROLE-2-CARBONITRILE - Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4′-fluoro-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-indol]-5′-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, hormone-dependent carcinomas; treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; or treating symptoms of premenstrual syndrome using one or more of these polymorphs, solvates, or hydrate. | 12-18-2008 |
Patent application number | Description | Published |
20100019513 | Window lock keeper - An improved sash lock and keeper for a sash window assembly is disclosed. The sash window includes an upper sash window and a lower sash window. Each of the sashes is mounted within opposed guide rails which permit at least one of the sashes to travel slidably therein. | 01-28-2010 |
20110248516 | Sash lock with signal - A sash lock comprises a housing, latch member, activator arm, and trigger. The latch member is spring biased to slide from an unlocked position towards a locked position. The activator arm and trigger are pivotally mounted within the housing, with a torsion spring biasing the trigger relative to the activator arm, to cause the activator arm to pivot and contact the latch member. When the latch member is moved to the unlocked position, the biased activator arm engages the latch member to retain it in the unlocked position, while the biased trigger member pivots to have a portion protrude out of the housing. Upon closing the sash member, an angled surface of a keeper contacts a curved surface of the protruding trigger to cause it to counter-rotate and drive the activator arm to disengage from the latch member and automatically permit biasing of the latch member into the locked position. | 10-13-2011 |
20120284993 | Screwless Sash Lock for Metal and Plastic Window Sashes and the Like - A lock adapted for attachment to a sash window/door without screws comprises: a shaft with a cam secured thereon is rotatably secured to a housing, with the cam disposed within a housing cavity and rotatable therefrom out of an opening, into an extended position. The housing may be a single integrally formed wall that preferably has a flat bottom surface. A first attachment leg protrudes out from the housing cavity to extend beyond the bottom surface, with a foot thereon extending beyond a first end of the housing. A second attachment leg protrudes out the housing cavity second end, with a foot thereon oriented toward the housing first end, and a locking tab extends from the housing bottom surface. Installation of the screwless sash lock is by receiving the first foot, second foot, and locking tab within correspondingly positioned openings in the window/door rail, through sequenced rotational and sliding motion. | 11-15-2012 |
20120313387 | Force Entry Resistant Sash Lock - An improved forced entry resistant sash lock comprises a housing, a shaft rotatably mounted thereto, a locking spring, and a locking cam and a delay cam rotatably and fixedly mounted to the shaft, respectively. The delay cam selectively engages and drives the locking cam between a locked position and an unlocked position. Locking spring biasing causes engagement with a locking cam opening to lock the cam when in the latch-locked position, with engagement to a depth permitting releasable detent engagement in a delay cam recess. Selective engagement and driving of the locking cam comprises a first portion of delay cam rotation being without driven locking cam rotation, and a second portion causing driven locking cam rotation from a retracted position into a protruding position. Selective engagement is by contact between corresponding protrusions on the delay and locking cams. Shaft/delay cam counter-rotation to unlock the latch proceeds in a reverse manner. | 12-13-2012 |
20140013552 | Sash Window and Door Transportation Clip Assembly - A clip assembly may safely secure sliding sashes of a window or door during transportation, and, in one embodiment, be comprised of a strap member and a pawl member. The strap member may be comprised of a bumper portion, and a strap portion extending therefrom, where the strap portion may have a plurality of teeth formed within the thickness of the strap. The pawl member may have a pair of sidewalls supported by a top wall and an intermediate wall. The top wall may have a protrusion which includes a plurality of pawl teeth formed to complement the strap teeth, and be located proximate to the intermediate wall. The strap may be introduced through the gap between the top rail of an upper sash and bottom rail of the second sash, to then be inserted into the pawl, and thereby be retained by the respective teeth to secure the sashes. | 01-16-2014 |
20140306462 | Window Vent Stop with Flexible Side Engagement Pieces - A window vent stop for use in a sliding sash window assembly or a sliding door assembly. The vent stop has a housing adapted to be disposed in a recess in the non-movable sash member. This housing includes a cavity with a bottom plate therein. The tumbler has at least one pivot for pivotally securing the tumbler to the housing for movement between an extended position, to prevent movement of the sliding member and a retracted position, to allow movement of the sliding member. Also within the housing is a spring for biasing the tumbler. The housing has one or more flexible members extending from the end walls of the housing that secure the housing to an opening in a window sash when a portion of the window sash is positioned between the underside of a lip on said housing and the flexible member. | 10-16-2014 |
Patent application number | Description | Published |
20090054423 | Niacin receptor agonists, compositions containing such compounds and methods of treatment - The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included. | 02-26-2009 |
20090054506 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use - Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 02-26-2009 |
20090176854 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 07-09-2009 |
20110039860 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT - Compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof is disclosed. The compounds are useful for treating diabetes, inflammation, atherosclerosis, hypertension, pain and the like. Pharmaceutical compositions and methods of use are also included. | 02-17-2011 |
20110172256 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 07-14-2011 |
20130012511 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver. | 01-10-2013 |
Patent application number | Description | Published |
20120100213 | PHARMACEUTICAL FORMULATIONS OF A SUBSTITUTED DIAMINOPURINE - Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease. | 04-26-2012 |
20140093566 | PHARMACEUTICAL FORMULATIONS OF A SUBSTITUTED DIAMINOPURINE - Provided herein are pharmaceutical formulations, comprising 4-((9-((3S)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease. | 04-03-2014 |